Midazolam suppresses ischemia/reperfusion-induced cardiomyocyte apoptosis by inhibiting the JNK/p38 MAPK signaling pathway
Myocardial ischemia/reperfusion (I/R) injury causes irreversible injury to the heart, causing mainly acute myocardial infarction. Midazolam is a benzodiazepine commonly utilized in anesthesia and intensive care. Research has indicated midazolam plays a critical role in many diseases. However, the function of midazolam in myocardial injury induced by I/R warrants further investigation. The infarct size was examined through 2,3,5-triphenyl tetrazolium chloride (TTC) staining. The CK-MB, LDH, and AST levels were tested using commercial kits. Cell apoptosis was determined through TUNEL or flow cytometry assays. Bax, Bcl-2, cleaved caspase-3, p-p38, p38, p-JNK, JNK, p-ERK, and ERK expression was examined through western blot. In our study, midazolam was shown to suppress the infarct size and myocardial enzyme leakage in I/R rats. Additionally, midazolam was found to retard cardiomyocyte apoptosis. The JNK/p38 MAPK signaling pathway in I/R rats was inhibited by midazolam. Our findings demonstrated that in H/R-mediated H9C2 cells, anisomycin abolished the suppressive effects of midazolam on the JNK/p38 MAPK signaling pathway. Next, exploration discovered that anisomycin abolished the cytoprotective effects of midazolam on H/R-treated H9C2 cell apoptosis. Midazolam retarded I/R-induced cardiomyocyte apoptosis by inhibiting the JNK/p38 MAPK signaling pathway. These results may provide new insight into the treatment of myocardial I/R injury.